DongKook Pharmaceutical stock gains 4.15 percent on growth signals
Published on 09/24/2026 at 23:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DongKook Pharmaceutical stock rose 4.15 percent to KRW 21,350 on the KOSDAQ market on September 23, 2026, giving the company a market capitalization of KRW 963,113,594,450. The move came as fresh product developments and double-digit quarterly growth strengthened the company story.
Q2 revenue reaches KRW 259 billion
ATS View reports that DongKook Pharmaceutical generated KRW 259 billion in Q2 2026 revenue, up 10.9 percent from the same quarter a year earlier. Operating profit reached KRW 26.1 billion, equal to a 10.1 percent margin, while net income was KRW 17.2 billion.
The quarter also marked a sequential increase in revenue from KRW 251 billion in Q1 2026 to KRW 259 billion in Q2. Operating profit moved in the opposite direction, falling from KRW 27.3 billion to KRW 26.1 billion, making margin development an important measure for the next report.
Overseas sales accelerate sharply
DongKook Pharmaceutical's international business supplied the clearest growth comparison in the first half of 2026. KOSAI reports first-half overseas revenue of KRW 73.3 billion, up 94.7 percent year over year, while total first-half revenue reached KRW 509.9 billion.
The same review links the international expansion to Centellian24 cosmetics, whose Q2 overseas sales increased 566 percent year over year. That contrast matters: domestic sales grew 4.1 percent in the first half, so overseas demand is becoming the faster growth channel within the portfolio.
Yuresco and injections add catalysts
On September 23, 2026, ATS View listed reports that DongKook Pharmaceutical's Yuresco prostate-treatment product held a 76.3 percent share of the comparable dutasteride and tadalafil combination market. The company is also presenting DK-LADs, a long-acting injection platform, at the CPHI event in Milan.
KOSAI describes a three-month leuprorelin depot formulation as having completed Phase 3 development, with a planned 2027 launch. It also reports a planned KRW 60 billion investment in injectable production capacity, targeted to raise capacity to 2.5 times the existing level.
Stock gains with room to recover
DongKook Pharmaceutical stock stood at KRW 21,350 on September 23, 2026, after rising KRW 850 from the previous close of KRW 20,500. The 52-week range was KRW 16,260 to KRW 31,250, leaving the latest price KRW 9,900 below the yearly high and KRW 5,090 above the low.
DongKook Pharmaceutical at a glance
- Company: DongKook Pharmaceutical Co., Ltd.
- Ticker: 086450
- Trading venue: KRX KOSDAQ
- Price (as of September 23, 2026): KRW 21,350
- Market capitalization: KRW 963,113,594,450 (as of September 23, 2026)
- 52-week range: KRW 16,260-31,250 (as of September 23, 2026)
- Sector / Industry: Pharmaceuticals
